An announcement from Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) is now available.
Venus Medtech has provided an update on its progress towards resuming trading on the Hong Kong Stock Exchange, following a period of suspension due to Unauthorized Transactions. The company has conducted forensic investigations and internal control reviews, and it is taking steps to meet the Stock Exchange’s resumption guidance, including addressing issues related to management integrity and internal controls. While most disputed transactions have been resolved, an RMB80 million loan remains outstanding, with arbitration proceedings underway.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a company based in China, primarily focused on the development, manufacturing, and commercialization of innovative medical devices. The company integrates research and development, clinical development, and commercialization, and it continues its operations without significant disruption despite recent financial irregularities.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$2.48B
See more data about 2500 stock on TipRanks’ Stock Analysis page.